These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 12382524)

  • 1. Critical appraisal of IFN-alpha-based adjuvant therapy in stage II-III malignant melanoma.
    Eggermont AM
    Expert Rev Anticancer Ther; 2002 Oct; 2(5):563-9. PubMed ID: 12382524
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma.
    Kirkwood JM; Manola J; Ibrahim J; Sondak V; Ernstoff MS; Rao U;
    Clin Cancer Res; 2004 Mar; 10(5):1670-7. PubMed ID: 15014018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An updated analysis of 4 randomized ECOG trials of high-dose interferon in the adjuvant treatment of melanoma.
    Najjar YG; Puligandla M; Lee SJ; Kirkwood JM
    Cancer; 2019 Sep; 125(17):3013-3024. PubMed ID: 31067358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant therapy in melanoma.
    Mohr P; Weichenthal M; Hauschild A
    Onkologie; 2003 Jun; 26(3):227-33. PubMed ID: 12845206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991.
    Eggermont AM; Suciu S; Testori A; Kruit WH; Marsden J; Punt CJ; Santinami M; Salès F; Schadendorf D; Patel P; Dummer R; Robert C; Keilholz U; Yver A; Spatz A
    Eur J Cancer; 2012 Jan; 48(2):218-25. PubMed ID: 22056637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost effectiveness and cost utility of adjuvant interferon alpha in cutaneous melanoma: a review.
    Crott R
    Pharmacoeconomics; 2004; 22(9):569-80. PubMed ID: 15209526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190.
    Kirkwood JM; Ibrahim JG; Sondak VK; Richards J; Flaherty LE; Ernstoff MS; Smith TJ; Rao U; Steele M; Blum RH
    J Clin Oncol; 2000 Jun; 18(12):2444-58. PubMed ID: 10856105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does adjuvant systemic therapy with interferon-alpha for stage II-III melanoma prolong survival?
    Eggermont AM; Punt CJ
    Am J Clin Dermatol; 2003; 4(8):531-6. PubMed ID: 12862495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant interferon-α for the treatment of high-risk melanoma: An individual patient data meta-analysis.
    Ives NJ; Suciu S; Eggermont AMM; Kirkwood J; Lorigan P; Markovic SN; Garbe C; Wheatley K;
    Eur J Cancer; 2017 Sep; 82():171-183. PubMed ID: 28692949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role interferon-alpha in malignant melanoma remains to be defined.
    Eggermont AM
    Eur J Cancer; 2001 Nov; 37(17):2147-53. PubMed ID: 11677100
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-dose adjuvant interferon for stage III malignant melanoma.
    Inman JL; Russell GB; Savage P; Levine EA
    Am Surg; 2003 Feb; 69(2):127-30. PubMed ID: 12641352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant use of interferon alpha 2b is not justified in patients with stage IIb/III melanoma.
    Bajetta E
    Nat Clin Pract Oncol; 2008 Jan; 5(1):4-5. PubMed ID: 18043604
    [No Abstract]   [Full Text] [Related]  

  • 13. Adjuvant Therapy for Melanoma.
    Agha A; Tarhini AA
    Curr Oncol Rep; 2017 May; 19(5):36. PubMed ID: 28417343
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quality-of-life-adjusted survival analysis of high-dose adjuvant interferon alpha-2b for high-risk melanoma patients using intergroup clinical trial data.
    Kilbridge KL; Cole BF; Kirkwood JM; Haluska FG; Atkins MA; Ruckdeschel JC; Sock DE; Nease RF; Weeks JC
    J Clin Oncol; 2002 Mar; 20(5):1311-8. PubMed ID: 11870174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis.
    Mocellin S; Pasquali S; Rossi CR; Nitti D
    J Natl Cancer Inst; 2010 Apr; 102(7):493-501. PubMed ID: 20179267
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma.
    Eggermont AM; Suciu S; Testori A; Santinami M; Kruit WH; Marsden J; Punt CJ; Salès F; Dummer R; Robert C; Schadendorf D; Patel PM; de Schaetzen G; Spatz A; Keilholz U
    J Clin Oncol; 2012 Nov; 30(31):3810-8. PubMed ID: 23008300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant therapy with high-dose interferon alpha 2b in patients with high-risk stage IIB/III melanoma.
    Kirkwood JM; Tarhini AA; Moschos SJ; Panelli MC
    Nat Clin Pract Oncol; 2008 Jan; 5(1):2-3. PubMed ID: 18030300
    [No Abstract]   [Full Text] [Related]  

  • 18. Postsurgical adjuvant therapy for melanoma. Evaluation of a 3-year randomized trial with recombinant interferon-alpha after 3 and 5 years of follow-up.
    Rusciani L; Petraglia S; Alotto M; Calvieri S; Vezzoni G
    Cancer; 1997 Jun; 79(12):2354-60. PubMed ID: 9191523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial.
    Eggermont AM; Suciu S; MacKie R; Ruka W; Testori A; Kruit W; Punt CJ; Delauney M; Sales F; Groenewegen G; Ruiter DJ; Jagiello I; Stoitchkov K; Keilholz U; Lienard D;
    Lancet; 2005 Oct; 366(9492):1189-96. PubMed ID: 16198768
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial.
    Hansson J; Aamdal S; Bastholt L; Brandberg Y; Hernberg M; Nilsson B; Stierner U; von der Maase H;
    Lancet Oncol; 2011 Feb; 12(2):144-52. PubMed ID: 21256809
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.